IP Library Granted Patent US 7,863,452
Granted Patent B2
US 7,863,452 · App. 12/356,282 · Granted Jan 4, 2011

Process for production of piperidine derivatives

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,863,452
App. No.
12/356,282
Granted
Jan 4, 2011
Kind
B2
Abstract

Processes are disclosed for preparing piperidine derivative compounds of the formulae I, II or III: The processes involve reacting a compound of formula Ia, IIa or IIIa with isobutyrate or an isobutyrate equivalent.

Claims (36)

1. A process for preparing a piperidine derivative compound of formula III:

wherein

R 4 is selected from the group comprising H, alkyl, and aryl;

A, B, and D are the substituents of their rings, each of which may be different or the same, and are selected from the group consisting of hydrogen, fluorine, chlorine, alkyl, aryl, hydroxyl, alkoxy, and aryloxy;

said process comprising:

(a) reacting a compound of formula VIIa

wherein

X is a group chosen from chlorine, bromine, iodine, —OSO 2 R 5 , and diazonium salt displaceable via oxidative metallic addition; and

LG is a leaving group displaceable by a secondary amine, said leaving group chosen from chlorine, bromine, iodine, and —OSO 2 R 5 , wherein R 5 is chosen from alkyl, fluoro, fluoroalkyl, aryl, and substituted aryl, or LG is a group able to be converted to said leaving group displaceable by a secondary amine, said leaving group chosen from chlorine, bromine, iodine, and —OSO 2 R 5 ;

with an isobutyrate equivalent of formula IV

wherein R 8 is a trialkylsilyl,

in the presence of a transition metal catalyst having a metal selected from the group comprising of Ni and Pd, and ZnF 2 to provide a compound of formula VII

(b) reacting the compound of formula VII with a piperidine compound of formula IX

in the presence of a base to provide the compound of formula III.

2. A process according to claim 1 , wherein the compound of formula VII, in which A is hydrogen and LG is a methane or toluene sulfonate, is prepared by reacting a compound of formula VIIab

with the compound of formula IV, followed by reaction with methanesulfonyl chloride or toluenesulfonylchloride.

3. A process according claim 1 wherein X is displaceable by the isobutyrate equivalent of formula IV by reaction in the presence of a phosphorous compound chosen from trialkyl phosphine, triaryl phosphine, and mixed alkyl/aryl phosphine, and the transition metal catalyst.

4. A process according to claim 1 wherein R 8 is trimethylsilyl.

5. A process according claim 1 for preparing a piperidine derivative compound of formula III wherein A, B and C are hydrogen and R 4 is methyl, comprising:

(a) reacting a compound of formula XV

with an isobutyrate equivalent of formula IVa

in the presence of Pd(0) catalyst, a trialkyl or triaryl phosphine, and ZnF 2 to provide a compound of formula XVIII

(b) converting the compound of formula XVIII to a compound of formula XVIIIa

(c) reacting the compound of formula XVIIIa with a piperidine compound of formula XIXa

in the presence of a base to provide a compound of formula 18

6. A process according to claim 5 wherein, the compound of XV is prepared by reacting a compound of formula XVa

with 1-bromo-4-iodobenzene in the presence of a transition metal catalyst.

7. A process for preparing a piperidine derivative compound of formula II

wherein A, B, C and R 4 are hydrogen, comprising:

(a) reacting a compound of formula XV

with an isobutyrate equivalent of formula IVa

in the presence of Pd(0) catalyst, a trialkyl or triaryl phosphine, and ZnF 2 to provide a compound of formula XVIII

(b) converting the compound of formula XVIII to a compound of formula XVIIIa

(c) reacting the compound of formula XVIIIa with a piperidine compound of formula XIXa

in the presence of a base to provide a compound of formula 18

(d) oxidizing the acetylene in compound 18 to a ketone, reducing the ketone to an alcohol and saponifying the methyl ester to provide fexofenadine.

Assignments (14)
CHANGE OF NAME Recorded May 20, 2025
From: ALBANY MOLECULAR RESEARCH, INC.
To: CURIA GLOBAL, INC.
Reel/Frame 071298/0097 →
ASSIGNMENT OF SECURITY INTEREST IN INTELLECTUAL PROPERTY, RECORDED ON SEPTEMBER 1, 2017, AT REEL/FRAME 043746/0621 Recorded Mar 17, 2025
From: BARCLAYS BANK PLC, AS EXISTING AGENT
To: APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT
Reel/Frame 070531/0279 →
SECURITY INTEREST Recorded Sep 6, 2021
From: CURIA GLOBAL, INC. (FKA ALBANY MOLECULAR RESEARCH, INC.); CURIA MASSACHUSETTS, INC. (FKA AMRI BURLINGTON, INC.); CURIA WISCONSIN, INC. (FKA CEDARBURG PHARMACEUTICALS, INC.); CURIA INDIANA, LLC (FKA AMRI SSCI, LLC); CURIA NEW MEXICO, LLC (FKA OSO BIOPHARMACEUTICALS MANUFACTURING, LLC); CURIA IP HOLDINGS, LLC
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 057423/0665 →
RELEASE OF SECURITY INTEREST Recorded Oct 29, 2020
From: MORGAN STANLEY SENIOR FUNDING, INC., AS COLLATERAL AGENT
To: ALBANY MOLECULAR RESEARCH, INC.; AMRI BURLINGTON, INC.; CEDARBURG PHARMACEUTICALS, INC.; EUTICALS INC.; OSO BIOPHARMACEUTICALS MANUFACTURING, LLC
Reel/Frame 054252/0687 →
CORRECTIVE ASSIGNMENT TO CORRECT THE INCORRECT PATENT NO. 7541537 PREVIOUSLY RECORDED AT REEL: 034045 FRAME: 0951. ASSIGNOR(S) HEREBY CONFIRMS THE SECURITY INTEREST. Recorded Aug 14, 2018
From: ALBANY MOLECULAR RESEARCH, INC.; ALO ACQUISITION LLC; AMRI BURLINGTON, INC.; AMRI RENSSELAER, INC.; CEDARBURG PHARMACEUTICALS, INC.; OSO BIOPHARMACEUTICALS MANUFACTURING, LLC
To: BARCLAYS BANK PLC, AS THE COLLATERAL AGENT
Reel/Frame 046796/0352 →
SECOND LIEN SECURITY AGREEMENT Recorded Sep 1, 2017
From: ALBANY MOLECULAR RESEARCH, INC.; AMRI BURLINGTON, INC.; CEDARBURG PHARMACEUTICALS, INC.; EUTICALS INC.; OSO BIOPHARMACEUTICALS MANUFACTURING LLC-BY ITS SOLE MEMBER:ALO ACQUISITION LLC
To: MORGAN STANLEY SENIOR FUNDING, INC.
Reel/Frame 043746/0657 →
FIRST LIEN SECURITY AGREEMENT Recorded Sep 1, 2017
From: ALBANY MOLECULAR RESEARCH, INC.; AMRI BURLINGTON, INC.; CEDARBURG PHARMACEUTICALS, INC.; EUTICALS INC.; OSO BIOPHARMACEUTICALS MANUFACTURING, LLC-BY ITS SOLE MEMBER: ALO ACQUISITION LLC
To: BARCLAYS BANK, PLC AS COLLATERAL AGENT
Reel/Frame 043746/0621 →
RELEASE OF SECURITY INTEREST Recorded Aug 31, 2017
From: BARCLAYS BANK PLC, AS COLLATERAL AGENT
To: ALBANY MOLECULAR RESEARCH, INC.; ALO ACQUISITION LLC; AMRI BURLINGTON, INC.; AMRI RENSSELAER, INC.; CEDARBURG PHARMACEUTICALS, INC.; OSO BIOPHARMACEUTICALS MANUFACTURING, LLC; AMRI SSCI, LLC; EUTICALS INC.
Reel/Frame 043742/0085 →
SECURITY INTEREST Recorded Oct 24, 2014
From: ALBANY MOLECULAR RESEARCH, INC.; ALO ACQUISITION LLC; AMRI BURLINGTON, INC.; AMRI RENSSELAER, INC.; CEDARBURG PHARMACEUTICALS, INC.; OSO BIOPHARMACEUTICALS MANUFACTURING, LLC
To: BARCLAYS BANK PLC, AS THE COLLATERAL AGENT
Reel/Frame 034045/0951 →
RELEASE OF SECURITY INTEREST Recorded Jul 9, 2014
From: WELLS FARGO
To: ALBANY MOLECULAR RESEARCH, INC.
Reel/Frame 033283/0357 →
SECURITY AGREEMENT Recorded Apr 20, 2012
From: ALBANY MOLECULAR RESEARCH, INC.; AMRI BURLINGTON, INC.; AMRI BOTHELL RESEARCH CENTER, INC.; AMRI RENESSELAER, INC.
To: WELLS FARGO BANK, NATIONAL ASSOCIATION
Reel/Frame 028078/0227 →
TERMINATION Recorded Apr 19, 2012
From: BANK OF AMERICA, N.A.
To: ALBANY MOLECULAR RESEARCH, INC.; AMRI BOTHELL RESEARCH CENTER, INC.; AMRI BURLINGTON, INC.; AMRI RENESSELAER, INC.
Reel/Frame 028072/0335 →
INTELLECTUAL PROPERTY SECURITY AGREEMENT Recorded Jun 6, 2011
From: ALBANY MOLECULAR RESEARCH, INC.; AMRI RENSSELAER, INC.; AMRI BOTHELL RESEARCH CENTER, INC.; AMRI BURLINGTON, INC.
To: BANK OF AMERICA, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 026397/0001 →
MERGER Recorded Feb 8, 2010
From: AMR TECHNOLOGY, INC.
To: ALBANY MOLECULAR RESEARCH, INC.
Reel/Frame 023905/0317 →